Advertisement

Psychopharmacology

, Volume 83, Issue 1, pp 126–128 | Cite as

An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients

  • G. Chouinard
  • L. Annable
  • J. Bradwejn
Rapid Communication

Abstract

In a 6-week open-label study, ten newly admitted depressed patients were treated with tomoxetine, a selective inhibitor of noradrenaline reuptake. After 7 days of drug washout, patients were given an initial dose of 40 mg/day which was gradually increased to a maximum of 70 mg/day (median 50 mg/day). There was a statistically (P<0.001) and clinically significant improvement in the mean symptomatology of the patients measured on the Hamilton Depression Rating Scale. The drug had an early onset of action, a specific effect on mood and no sedative properties.

Key words

Tomoxetine LY139603 Antidepressant Affective disorder Depression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307–317Google Scholar
  2. Diagnostic and Statistical Manual of Mental Disorders (3rd ed) (1980) American Psychiatric Association, Washington, DCGoogle Scholar
  3. Lilly Research Laboratories (1982) Clinical Investigation Manual LY139603. Eli Lilly and Company, Manual Identification Number: AS-6110Google Scholar
  4. Wong DT, Threlkeld PG, Best KL, Bymaster FP (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61–65Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • G. Chouinard
    • 1
    • 2
  • L. Annable
    • 1
    • 2
  • J. Bradwejn
    • 1
    • 2
  1. 1.Clinical Psychopharmacology Unit, Allan Memorial InstituteRoyal Victoria HospitalMontrealCanada
  2. 2.Department of PsychiatryMcGill UniversityMontrealCanada

Personalised recommendations